TrialBlood and lymphatic cancer : targets and therapy2025

Phase II Trial of an Orelabrutinib-Based Combination Therapy in Newly Diagnosed Primary Central Nervous System Lymphoma.

Yajing Zhao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.